Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/04/24
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 09/30/24
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19GlobeNewsWire • 09/13/24
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?Zacks Investment Research • 08/28/24
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation PathwayGlobeNewsWire • 08/28/24
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to BuyZacks Investment Research • 08/12/24
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024GlobeNewsWire • 07/31/24
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024GlobeNewsWire • 05/22/24
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024GlobeNewsWire • 04/29/24
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobeNewsWire • 03/27/24
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/24
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024GlobeNewsWire • 02/21/24
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19GlobeNewsWire • 01/08/24
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023GlobeNewsWire • 11/13/23
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/08/23
Atea Pharmaceuticals Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 11/08/23
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023GlobeNewsWire • 11/01/23
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/23